Polycystic Ovary Syndrome – Causes, Symptoms, Therapy and Diet

Polycystic ovary syndrome (PCOS), a condition frequently abbreviated from its full designation, represents one of the most prevalent endocrine disorders observed among women of reproductive age. Often referred to as a "21st-century lifestyle disease," its increasing incidence and multifaceted pathogenic mechanisms have drawn significant clinical attention. Epidemiological estimates suggest that between 4% and 15% of women in their childbearing years are affected by PCOS, with this broad range attributable to variations in diagnostic criteria employed across European and North American healthcare systems. The identification of PCOS relies on guidelines established by distinct medical societies, which further complicates the standardization of diagnostic protocols.

Polycystic ovary syndrome (PCOS) represents a multifaceted endocrine-metabolic disorder whose pathogenesis arises from the interplay of diverse biological and environmental determinants. There is no singular, definitively established causative factor; rather, the condition emerges from a confluence of genetic predispositions, hormonal imbalances, and lifestyle influences. While specific genes conferring heightened susceptibility to PCOS remain unidentified, epidemiological evidence demonstrates a markedly elevated prevalence among first-degree relatives, suggesting a strong hereditary component. Beyond genetic factors, endocrine dysfunctions play a pivotal role, including ovarian hyperandrogenism, peripheral insulin resistance, and dysregulated insulin secretion by pancreatic β-cells. Environmental contributors—particularly excess adiposity, especially visceral obesity—further exacerbate risk by amplifying systemic inflammation and metabolic derangement. Critically, adipose tissue functions as an endocrine organ, secreting bioactive adipokines that disrupt hormonal homeostasis and perpetuate the pathophysiological cycle underlying PCOS.

The diagnosis of polycystic ovary syndrome (PCOS) necessitates meeting at least two of the three fundamental diagnostic criteria. The first criterion pertains to irregular or absent ovulation. The second involves symptoms indicative of hyperandrogenism, which may be identified through clinical observations or biochemical assays. The third criterion is the presence of polycystic ovarian morphology, detectable via ultrasonographic examination. Prior to confirming a diagnosis, it is imperative to exclude other conditions that may mimic PCOS symptoms, including hormonally active tumors capable of inducing hyperandrogenic manifestations. In the diagnostic process, the assessment of total testosterone levels is significant, though the free testosterone fraction offers greater precision, albeit with potential limitations in availability. Alternatively, the free androgen index (FAI) may be utilized. It is crucial to note that oral contraceptives substantially alter hormonal profiles, including testosterone concentrations; thus, their discontinuation for a minimum of three months prior to testing is advised. Additional evaluations, such as prolactin and luteinizing hormone (LH) measurements, while not definitive for diagnosis, provide valuable insights into the patient’s fertility status. Excess body weight may distort these results, as adipose tissue influences hormonal secretion. Given the frequent co-occurrence of insulin resistance in women with PCOS, an assessment of carbohydrate metabolism—including a 75-g oral glucose tolerance test—is essential. A more precise diagnostic tool is the calculation of the fasting glucose-to-insulin ratio, with values below 4.5 suggesting the presence of insulin resistance.

The clinical manifestations of polycystic ovary syndrome (PCOS) exhibit substantial variability depending on the patient’s life stage, with one of the most distressing consequences being infertility arising from hormonal dysregulation. Menstrual irregularities—encompassing both oligomenorrhea and episodes of excessive bleeding—may lead to complications such as anemia, underscoring the necessity for routine laboratory evaluations (e.g., complete blood counts). In women diagnosed with PCOS, even after conception, there is an elevated risk of spontaneous miscarriage, preterm delivery, and metabolic complications, including gestational diabetes and hypertension—particularly in patients with concurrent obesity. Furthermore, hyperandrogenism (excess androgen activity) manifests through virilization features: hirsutism, male-pattern baldness, and acne, which frequently impose psychological burdens. The syndrome also affects adolescent girls, in whom symptoms may be mistakenly attributed to normal pubertal changes; premature pubic hair development (before age 8) may warrant ovarian ultrasonography. Untreated PCOS results in anovulatory cycles, while chronic estrogen deficiency increases the risk of endometrial malignancies—further exacerbated by coexisting obesity, insulin resistance, and hypertension.

The effective management of polycystic ovary syndrome (PCOS) necessitates a multifaceted approach that addresses both the alleviation of physical symptoms and psychological support when the condition impacts the patient’s emotional well-being. In cases where obesity coexists with PCOS, the implementation of lifestyle modifications is essential, including the adoption of a personalized, nutritionally balanced dietary regimen and a structured, capacity-adjusted physical activity program. These interventions facilitate gradual weight loss, with even a modest 5% reduction in body weight yielding significant improvements in menstrual cycle regularity. Furthermore, such weight reduction may contribute to the restoration of physiological ovulation, the stabilization of menstrual patterns, and—consequently—an enhanced likelihood of conception. An additional benefit lies in the mitigation of hirsutism symptoms, namely excessive androgen-dependent hair growth, which substantially improves the patient’s overall well-being and quality of life.

Strategic dietary modification represents a cornerstone of therapeutic intervention for individuals diagnosed with polycystic ovary syndrome (PCOS). Contemporary research underscores that conventional dietary patterns among this demographic frequently exhibit high caloric density coupled with deficient micronutrient profiles. Transitioning to a diet centered on minimally processed, nutrient-dense foods—rich in diverse macro- and micronutrients—is strongly advised. Particular emphasis must be placed on the dietary fatty acid composition: reducing saturated fats (predominantly found in animal-derived products such as lard or suet) while prioritizing polyunsaturated fats, especially omega-3 fatty acids, which are abundant in oily marine fish, flaxseeds, and chia seeds. Although cholesterol’s role in atherogenesis remains a subject of scientific debate, excessive intake may exacerbate hormonal imbalances by influencing androgen synthesis. Regarding carbohydrates, complex variants from whole-grain products and legumes are preferred due to their fiber content and low glycemic index (GI). A low-GI diet facilitates glucose homeostasis, mitigates hyperinsulinemia, and reduces androgen secretion. Micronutrient deficiencies—particularly potassium, zinc, and magnesium—are prevalent in PCOS, alongside folic acid, which is critical during the preconception period. Vitamin D and calcium may aid menstrual cycle regulation, warranting inclusion of dairy and fish in the diet. Additionally, certain herbs (e.g., peppermint) and green tea demonstrate beneficial effects on androgen suppression and insulin sensitivity enhancement. Weight management necessitates not only a balanced diet but also a caloric deficit (500–1000 kcal/day). Physical activity should be tailored individually—moderate, consistent (at least 30 minutes daily), and aligned with the patient’s health status and capabilities. PCOS is a multifactorial condition whose treatment should integrate pharmacotherapy with lifestyle adjustments to alleviate symptoms, enhance fertility, and improve overall well-being.